Validation of PRKCB Immunohistochemistry as a Biomarker for the Diagnosis of Ewing Sarcoma

References

• WHO Classification of Tumours Editorial Board, editors. WHO classification of tumours of soft tissue and bone. 5th ed., Vol. 3. Lyon (France): IARC; 2020.
   Google Scholar
• Goldblum JR, Weiss SW, Folpe AL. Enzinger and Weiss’s soft tissue tumors. 6th ed. Philadelphia (PA): Saunders; 2013.
   Google Scholar
• Gibbs J, Henderson-Jackson E, Bui MM. Bone and soft tissue pathology: diagnostic and prognostic implications. Surg Clin North Am. 2016;96(5):915–62. doi:10.1016/j.suc.2016.06.003.
   PubMedGoogle Scholar
• Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011;11(8):541–57. doi:10.1038/nrc3087.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing’s family of tumors. Cancer Res. 2005;65(11):4633–44. doi:10.1158/0008-5472.CAN-04-2857.
   PubMedGoogle Scholar
• Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007;11(5):421–9. doi:10.1016/j.ccr.2007.02.027.
   PubMed Web of Science ®Google Scholar
• Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–5. doi:10.1038/359162a0.
   PubMed Web of Science ®Google Scholar
• Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, Zucker JM, Triche TJ, Sheer D, Turc-Carel C, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 1993;12(12):4481–7. doi:10.1002/j.1460-2075.1993.tb06137.x.
   PubMedGoogle Scholar
• Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, Thiery JP, Olschwang S, Philip I, Berger MP, et al. Chromosomes in Ewing’s sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet. 1988;32(2):229–38. doi:10.1016/0165-4608(88)90285-3.
   PubMedGoogle Scholar
• Lessnick SL, Braun BS, Denny CT, May WA. Multiple domains mediate transformation by the Ewing’s sarcoma EWS/FLI-1 fusion gene. Oncogene. 1995;10(3):423–31.
   PubMed Web of Science ®Google Scholar
• Zucman J, Delattre O, Desmaze C, Plougastel B, Joubert I, Melot T, Peter M, De Jong P, Rouleau G, Aurias A, et al. Cloning and characterization of the Ewing’s sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer. 1992;5(4):271–7. doi:10.1002/gcc.2870050402.
   PubMed Web of Science ®Google Scholar
• van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2010;28(12):1989–94. doi:10.1200/JCO.2009.24.5845.
   PubMedGoogle Scholar
• Sankar S, Lessnick SL. Promiscuous partnerships in Ewing’s sarcoma. Cancer Genet. 2011;204(7):351–65. doi:10.1016/j.cancergen.2011.07.008.
   PubMed Web of Science ®Google Scholar
• Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, Lessnick SL. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing’s sarcoma. Cancer Cell. 2006;9(5):405–16. doi:10.1016/j.ccr.2006.04.004.
   PubMed Web of Science ®Google Scholar
• Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24(16):7275–83. doi:10.1128/MCB.24.16.7275-7283.2004.
   PubMed Web of Science ®Google Scholar
• Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing’s sarcoma. Mol Cancer Res. 2006;4(11):851–9. doi:10.1158/1541-7786.MCR-06-0090.
   PubMed Web of Science ®Google Scholar
• Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, Kovar H. A molecular function map of Ewing’s sarcoma. PLoS One. 2009;4(4):e5415. doi:10.1371/journal.pone.0005415.
   PubMed Web of Science ®Google Scholar
• Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May WA. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene. 2008;27(23):3282–91. doi:10.1038/sj.onc.1210991.
   PubMedGoogle Scholar
• Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing’s sarcoma oncogenesis and therapeutic resistance. Oncogene. 2009;28(46):4126–32. doi:10.1038/onc.2009.262.
   PubMed Web of Science ®Google Scholar
• Siligan C, Ban J, Bachmaier R, Spahn L, Kreppel M, Schaefer K-L, Poremba C, Aryee DNT, Kovar H. EWS-FLI1 target genes recovered from Ewing’s sarcoma chromatin. Oncogene. 2005;24(15):2512–24. doi:10.1038/sj.onc.1208455.
   PubMedGoogle Scholar
• Richter GHS, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA. 2009;106(13):5324–9. doi:10.1073/pnas.0810759106.
   PubMed Web of Science ®Google Scholar
• Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing’s sarcoma. Clin Cancer Res. 2004;10(4):1344–53. doi:10.1158/1078-0432.ccr-03-0038.
   PubMed Web of Science ®Google Scholar
• Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, Gallego S, Ban J, Kovar H, Notario V. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing’s sarcoma cells. Cancer Res. 2006;66(20):9937–47. doi:10.1158/0008-5472.CAN-06-0927.
   PubMed Web of Science ®Google Scholar
• Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, Sorensen PH, Thiele CJ, Kim SJ. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet. 1999;23(2):222–7. doi:10.1038/13854.
   PubMed Web of Science ®Google Scholar
• Olsen SH, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol. 2006;19(5):659–68. doi:10.1038/modpathol.3800569.
   PubMedGoogle Scholar
• Yoshida A, Sekine S, Tsuta K, Fukayama M, Furuta K, Tsuda H. NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. Am J Surg Pathol. 2012;36(7):993–9. doi:10.1097/PAS.0b013e31824ee43c.
   PubMed Web of Science ®Google Scholar
• Kang SW, Wahl MI, Chu J, Kitaura J, Kawakami Y, Kato RM, Tabuchi R, Tarakhovsky A, Kawakami T, Turck CW, et al. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J. 2001;20(20):5692–702. doi:10.1093/emboj/20.20.5692.
   PubMedGoogle Scholar
• Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, Müller JM, Greschik H, Kirfel J, Ji S, et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature. 2010;464(7289):792–6. doi:10.1038/nature08839.
   PubMedGoogle Scholar
• Ohali A, Avigad S, Cohen IJ, Meller I, Kollender Y, Issakov J, Gelernter I, Goshen Y, Yaniv I, Zaizov R, et al. Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J Clin Oncol. 2003;21(20):3836–43. doi:10.1200/JCO.2003.05.059.
   PubMed Web of Science ®Google Scholar
• Amm HM, DeVilliers P, Srivastava AR, Diniz MG, Siegal GP, MacDougall M. Mandibular undifferentiated pleomorphic sarcoma: molecular analysis of a primary cell population. Clin Exp Dent Res. 2020;6(5):495–505. doi:10.1002/cre2.301.
   PubMedGoogle Scholar
• Wang K, Guo R, Siegal GP, Wei S. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification. Pathol Res Pract. 2019;215(9):152535. doi:10.1016/j.prp.2019.152535.
   PubMedGoogle Scholar
• Stevens TM, Qarmali M, Morlote D, Mikhail FM, Swensen J, Gatalica Z, Siegal GP, Conry RM. Malignant Ewing-like neoplasm with an EWSR1-KLF15 fusion: at the crossroads of a myoepithelial carcinoma and a Ewing-like sarcoma. A case report with treatment options. Int J Surg Pathol. 2018;26(5):440–7. doi:10.1177/1066896918755009.
   PubMedGoogle Scholar
• Welsh EA, Eschrich SA, Berglund AE, Fenstermacher DA. Iterative rank-order normalization of gene expression microarray data. BMC Bioinformatics. 2013;14:153. doi:10.1186/1471-2105-14-153.
   PubMedGoogle Scholar
• Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 2011;17(6):528–36. doi:10.1097/PPO.0b013e318238216e.
   PubMed Web of Science ®Google Scholar
• Surdez D, Benetkiewicz M, Perrin V, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes Ewing sarcoma growth. Cancer Res. 2012;72(17):4494–4503. doi:10.1158/0008-5472.CAN-12-0371.
   PubMed Web of Science ®Google Scholar
• Fitzgibbons PL, Bradley LA, Fatheree LA, Alsabeh R, Fulton RS, Goldsmith JD, Haas TS, Karabakhtsian RG, Loykasek PA, Marolt MJ, et al. Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med. 2014;138(11):1432–43. doi:10.5858/arpa.2013-0610-CP.
   PubMed Web of Science ®Google Scholar
• Gerschütz A, Heinsen H, Grünblatt E, Wagner AK, Bartl J, Meissner C, Fallgatter AJ, Al-Sarraj S, Troakes C, Ferrer I, et al. Neuron-specific alterations in signal transduction pathways associated with Alzheimer’s disease. J Alzheimers Dis. 2014;40(1):135–42. doi:10.3233/JAD-131280.
   PubMedGoogle Scholar